Ageing - Pipeline Review, H2 2014

Date: December 31, 2014
Pages: 50
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: AFDC2AA478BEN
Leaflet:

Download PDF Leaflet

Ageing - Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Ageing - Pipeline Review, H2 2014’, provides an overview of the Ageing’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Ageing, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ageing and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Ageing
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Ageing and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Ageing products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Ageing pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Ageing
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Ageing pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Ageing Overview
Therapeutics Development
Pipeline Products for Ageing - Overview
Pipeline Products for Ageing - Comparative Analysis
Ageing - Therapeutics under Development by Companies
Ageing - Therapeutics under Investigation by Universities/Institutes
Ageing - Pipeline Products Glance
Early Stage Products
Ageing - Products under Development by Companies
Ageing - Products under Investigation by Universities/Institutes
Ageing - Companies Involved in Therapeutics Development
Bioo Therapeutics
Neuralstem, Inc.
RepliCel Life Sciences, Inc.
RXi Pharmaceuticals Corporation
vida therapeutics inc.
Ageing - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
BIOO-4 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BIOO-7 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drugs for Ageing - Drug Profile
Product Description
Mechanism of Action
R&D Progress
metformin + sirolimus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MG-29 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MMP-26051 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MMP-26052 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NSI-189 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RCS-01 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
sirolimus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Alzheimer's Disease and Ageing - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TM-5441 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
V-2248 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ageing - Recent Pipeline Updates
Ageing - Dormant Projects
Ageing - Product Development Milestones
Featured News & Press Releases
Oct 09, 2014: RepliCel to Present Commercial and Clinical Update on RCS-01 at BioJapan 2014 World Business Forum
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Ageing, H2 2014
Number of Products under Development for Ageing - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Number of Products under Investigation by Universities/Institutes, H2 2014
Comparative Analysis by Early Stage Development, H2 2014
Products under Development by Companies, H2 2014
Products under Investigation by Universities/Institutes, H2 2014
Ageing - Pipeline by Bioo Therapeutics, H2 2014
Ageing - Pipeline by Neuralstem, Inc., H2 2014
Ageing - Pipeline by RepliCel Life Sciences, Inc., H2 2014
Ageing - Pipeline by RXi Pharmaceuticals Corporation, H2 2014
Ageing - Pipeline by vida therapeutics inc., H2 2014
Assessment by Monotherapy Products, H2 2014
Assessment by Combination Products, H2 2014
Number of Products by Stage and Target, H2 2014
Number of Products by Stage and Mechanism of Action, H2 2014
Number of Products by Stage and Route of Administration, H2 2014
Number of Products by Stage and Molecule Type, H2 2014
Ageing Therapeutics - Recent Pipeline Updates, H2 2014
Ageing - Dormant Projects, H2 2014

LIST OF FIGURES

Number of Products under Development for Ageing, H2 2014
Number of Products under Development for Ageing - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Number of Products under Investigation by Universities/Institutes, H2 2014
Comparative Analysis by Early Stage Products, H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Top 10 Targets, H2 2014
Number of Products by Stage and Top 10 Targets, H2 2014
Number of Products by Top 10 Mechanism of Actions, H2 2014
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014
Number of Products by Top 10 Routes of Administration, H2 2014
Number of Products by Stage and Top 10 Routes of Administration, H2 2014
Number of Products by Top 10 Molecule Types, H2 2014
Number of Products by Stage and Top 10 Molecule Types, H2 2014

COMPANIES MENTIONED

Bioo Therapeutics
Neuralstem, Inc.
RepliCel Life Sciences, Inc.
RXi Pharmaceuticals Corporation
vida therapeutics inc.

Ask Your Question

Ageing - Pipeline Review, H2 2014
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: